GLP-1, GIP & Glucagon: The Receptors Explained
Semaglutide, tirzepatide and retatrutide address different combinations of metabolic receptors. But what is a receptor, and how do GLP-1, GIP and glucagon differ? This overview explains the basics and identifies which signalling pathways each compound addresses in research.
What Is a Receptor? The Lock-and-Key Principle
A receptor is like a lock on the surface of a cell. When the right key — a signaling molecule — fits into it, a reaction is triggered inside the cell. Peptides such as semaglutide or tirzepatide are engineered keys designed to fit specific locks.
In metabolic research, three of these locks are especially important: GLP-1, GIP, and glucagon. Which peptide fits which lock determines its research profile.
GLP-1 — the Best-Known Satiety Pathway
GLP-1 (glucagon-like peptide-1) is the most thoroughly researched of these receptors. It sits in the pancreas, brain, and stomach, among other places, and plays a central role in blood-sugar and satiety signaling.
Semaglutide is a pure GLP-1 receptor agonist — it fits only this one lock and is regarded by many researchers as a reference molecule.
GIP — the Second Satiety Pathway
GIP (glucose-dependent insulinotropic polypeptide) is a second receptor closely linked to sugar metabolism. It gets interesting when a peptide docks onto both GLP-1 and GIP at the same time.
Tirzepatide is one such dual agonist — this dual action distinguishes it from pure GLP-1 substances and produces an independent research profile. With us: Glowjaro.
Glucagon — the Energy Counterpart
Glucagon is, in a sense, the counterpart of insulin and is involved in the body's energy supply. A peptide that also targets this receptor expands the research field by a third signaling pathway.
Retatrutide takes exactly this step and activates three receptors at once — GLP-1, GIP, and glucagon. This triple agonist is one of the newest tools in metabolic research. With us: Glowreta.
From Single to Multi-Agonists — Why It Changes Research
For a long time, it was thought that a peptide could operate only one lock. The development of dual (tirzepatide) and triple agonists (retatrutide) changed that. Research data suggest that activating several signaling pathways simultaneously can accomplish more together than the sum of the individual pathways — a central theme in current metabolic research.
Which Peptide for Which Receptor Research?
In the catalogue, Glowjaro (tirzepatide) targets GIPR and GLP-1R, and Glowreta (retatrutide) additionally targets the glucagon receptor. Published analytical reports apply only to the specifically identified sample or batch.
FAQ on GLP-1, GIP & Glucagon
What is a receptor agonist?
A receptor agonist is a molecule that binds to a receptor and triggers a reaction there — like a key that opens a lock.
What is the difference between GLP-1 and GIP?
GLP-1 and GIP are incretin hormones that bind to different receptors — GLP-1R and GIPR, respectively. Tirzepatide has agonist activity at both receptors; semaglutide targets GLP-1R.
What is a dual or triple agonist?
A peptide that binds to two (dual) or three (triple) different receptors at the same time. Tirzepatide is dual (GLP-1/GIP), retatrutide triple (GLP-1/GIP/glucagon).
Are these peptides intended for human use?
No. All research peptides mentioned here are intended exclusively for laboratory research and not for human use.
All three compounds compared side by side: GLP-1 peptides at a glance →
Sources
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989–1002. 10.1056/NEJMoa2032183
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205–216. 10.1056/NEJMoa2206038
- Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514–526. 10.1056/NEJMoa2301972
The studies cited refer to the clinical research status of the respective compounds and serve scientific context only. They do not constitute any statement about our research products, which are intended for laboratory research exclusively.
Disclaimer: Research peptides are offered exclusively for research purposes. They are not intended for human use. This article provides neutral scientific orientation and does not constitute medical claims or therapeutic promises.